If The Pink Sheet is right and Prasugrel isin fact going to an advisory panel in early 2009, my wild guess is a 65% chance of approval on the first review cycle. Of course, this number may go up or down sharply when the briefing docs are made public.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.